Hans Schikan brings over 25 years experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases. After the acquisition of Prosensa, he co-founded Pharvaris and currently serves on the board of several biopharma companies, He is also a former member of the top team of the Dutch Top Sector for Life Sciences and Health where the focus is on public-private partnerships. Furthermore, he is involved with two venture capital firms. Finally, he is former Special Envoy for vaccines, appointed by the Dutch Ministry of Health, to explore optimization in the production and scale-up of vaccines during the COVID-19 pandemic.